Your browser is no longer supported. Please, upgrade your browser.
ACRX AcelRx Pharmaceuticals, Inc. daily Stock Chart
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.62 Insider Own1.10% Shs Outstand90.32M Perf Week-12.18%
Market Cap138.85M Forward P/E- EPS next Y-0.27 Insider Trans0.86% Shs Float88.98M Perf Month-4.42%
Income-49.70M PEG- EPS next Q-0.08 Inst Own20.00% Short Float9.30% Perf Quarter63.21%
Sales4.40M P/S31.56 EPS this Y16.70% Inst Trans0.06% Short Ratio4.82 Perf Half Y21.83%
Book/sh-0.75 P/B- EPS next Y35.70% ROA-58.30% Target Price- Perf Year-21.00%
Cash/sh0.54 P/C3.18 EPS next 5Y- ROE107.40% 52W Range0.70 - 2.50 Perf YTD-18.01%
Dividend- P/FCF- EPS past 5Y2.60% ROI340.90% 52W High-30.80% Beta1.60
Dividend %- Quick Ratio2.80 Sales past 5Y-15.20% Gross Margin-51.30% 52W Low146.65% ATR0.20
Employees54 Current Ratio3.00 Sales Q/Q222.20% Oper. Margin- RSI (14)55.00 Volatility11.28% 12.17%
OptionableYes Debt/Eq- EPS Q/Q47.90% Profit Margin- Rel Volume0.57 Prev Close1.77
ShortableYes LT Debt/Eq- EarningsAug 10 AMC Payout- Avg Volume1.72M Price1.73
Recom2.00 SMA207.87% SMA5023.04% SMA20024.02% Volume979,520 Change-2.26%
Jul-20-20Downgrade Credit Suisse Neutral → Underperform
Nov-11-19Downgrade Credit Suisse Outperform → Neutral $7 → $2
Aug-05-19Resumed Credit Suisse Outperform
Jul-10-19Resumed Credit Suisse Outperform
Apr-24-19Resumed B. Riley FBR Buy $6.50
Feb-15-19Initiated Credit Suisse Outperform $7
Oct-23-18Initiated B. Riley FBR Buy $9
Oct-13-17Reiterated RBC Capital Mkts Outperform $6 → $5
Oct-13-17Downgrade Jefferies Buy → Hold
Jul-14-17Resumed Jefferies Buy $7
Sep-15-16Reiterated ROTH Capital Buy $11.25 → $15
Aug-05-16Downgrade Stifel Buy → Hold
Oct-30-15Upgrade Jefferies Hold → Buy
Oct-05-15Reiterated ROTH Capital Buy $8.50 → $10.50
Sep-02-15Initiated H.C. Wainwright Buy $8.50
Jul-10-15Resumed ROTH Capital Buy $7.50
May-06-15Reiterated Mizuho Neutral $5.50 → $3
May-05-15Reiterated RBC Capital Mkts Outperform $8 → $7
Mar-10-15Reiterated RBC Capital Mkts Outperform $12 → $8
Mar-09-15Downgrade Mizuho Buy → Neutral $14 → $5.59
Oct-15-20 10:26AM  
Oct-13-20 12:00PM  
Oct-12-20 08:59AM  
Sep-29-20 08:30AM  
Sep-23-20 06:48AM  
Sep-22-20 08:30AM  
Sep-14-20 08:30AM  
Sep-10-20 04:05PM  
Aug-31-20 05:00PM  
Aug-24-20 08:30AM  
Aug-19-20 08:30AM  
Aug-11-20 12:00PM  
Aug-10-20 05:45PM  
Aug-03-20 04:05PM  
Jul-27-20 12:31PM  
Jul-25-20 08:02AM  
Jul-23-20 08:40AM  
Jun-22-20 10:11PM  
Jun-17-20 06:33AM  
Jun-08-20 02:45PM  
Jun-04-20 08:13AM  
Jun-03-20 06:50PM  
Jun-01-20 08:00PM  
May-29-20 02:34PM  
May-27-20 09:54AM  
May-12-20 03:00AM  
May-11-20 06:45PM  
May-10-20 03:40PM  
May-08-20 12:00PM  
May-07-20 12:55PM  
May-06-20 12:30PM  
May-05-20 12:51PM  
May-04-20 04:35PM  
May-02-20 08:08AM  
Apr-30-20 06:00AM  
Apr-24-20 06:11AM  
Apr-23-20 09:09AM  
Apr-16-20 12:02PM  
Apr-02-20 12:28PM  
Apr-01-20 08:18AM  
Mar-27-20 12:00PM  
Mar-18-20 06:05AM  
Mar-17-20 05:50PM  
Mar-16-20 05:10PM  
Mar-11-20 07:50PM  
Mar-10-20 02:25PM  
Mar-06-20 11:55AM  
Feb-27-20 12:30PM  
Feb-24-20 10:28AM  
Feb-07-20 06:49AM  
Jan-27-20 05:45PM  
Jan-13-20 05:50PM  
Jan-07-20 10:21AM  
Jan-06-20 06:38AM  
Jan-03-20 12:00PM  
Dec-31-19 11:05AM  
Dec-30-19 05:21AM  
Dec-20-19 05:46PM  
Dec-13-19 08:39AM  
Nov-13-19 09:24AM  
Nov-12-19 05:40AM  
Nov-11-19 05:15AM  
Nov-06-19 07:25PM  
Nov-05-19 04:05PM  
Oct-30-19 10:33AM  
Oct-28-19 04:30PM  
Oct-25-19 10:30AM  
Oct-23-19 09:00AM  
Oct-16-19 07:00AM  
Aug-30-19 09:49AM  
Aug-15-19 04:05PM  
Aug-12-19 07:48AM  
Aug-05-19 09:24PM  
Aug-02-19 10:12AM  
Jul-25-19 10:33AM  
Jul-01-19 02:00PM  
Jun-28-19 06:53PM  
Jun-13-19 05:05PM  
Jun-06-19 08:26PM  
Jun-03-19 07:00AM  
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Angotti Vincent J.Chief Executive OfficerJun 15Buy1.337,54710,035468,757Jun 15 06:00 PM
EDWARDS MARK GDirectorNov 12Buy1.7825,00044,575243,750Nov 12 04:22 PM
Angotti Vincent J.Chief Executive OfficerNov 11Buy1.798,37914,973275,944Nov 12 06:07 AM